Skip to content

Efficacy evaluation of paravertebral injection of recombinant human interferon a -2B in the prevention of postherpetic neuralgia in dorsal root ganglion with high voltage and long duration pulse radio frequency

Efficacy evaluation of paravertebral injection of recombinant human interferon a -2B in the prevention of postherpetic neuralgia in dorsal root ganglion with high voltage and long duration pulse radio frequency

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100050100
Enrollment
Unknown
Registered
2021-08-16
Start date
2021-08-16
Completion date
Unknown
Last updated
2022-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Herpes zoster neuralgia

Interventions

Group H:Paravertebral injection of recombinant human interferon a -2B in dorsal root ganglion with high voltage and long time pulse radio frequency
Group C:Paravertebral injection of dorsal root ganglion with high voltage and long duration pulse radio frequency (excluding recombinant human interferon a -2B)
Group I:Paravertebral injection of recombinant human interferon alpha-2b

Sponsors

Jiaxing First Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with acute herpetic neuralgia with thoracic or lumbar ganglion involvement, disease duration 3.

Exclusion criteria

Exclusion criteria: 1. There is infection or tumor at the puncture site; 2. Those who are allergic to drugs such as recombinant human interferon a-2b and compound tamethasone; 3. Patients with severe cardiovascular and cerebrovascular diseases, liver and kidney dysfunction, and abnormal coagulation function; 4. Diabetic patients with poor blood sugar control and systemic failure; 5. Those who suffer from mental illness and cannot cooperate with the operation.

Design outcomes

Primary

MeasureTime frame
Pain score;The dosage of analgesics;

Secondary

MeasureTime frame
Blood gal-3 and IL-6 levels;

Countries

China

Contacts

Public ContactFei Yong

Jiaxing First Hospital

15712633103@163.com+8615712633103

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026